GLP‑1 users often regain weight after stopping

Glucagon-like peptide 1 drugs such as Wegovy, Ozempic, and Zepbound lower appetite while people take them, but weight often returns after they stop. (jamanetwork.com) (nature.com) These medicines mimic gut hormones that slow stomach emptying and increase fullness, so people tend to eat less and lose weight over months. In obesity care, doctors generally use them as long-term treatment, not a short reset. (nejm.org) (jamanetwork.com) The clearest semaglutide evidence comes from the STEP 1 extension. After 68 weeks on semaglutide 2.4 milligrams plus lifestyle support, participants who stopped treatment regained 11.6 percentage points of lost weight by week 120. (pmc.ncbi.nlm.nih.gov) That worked out to about two-thirds of the weight they had lost coming back within one year off the drug. Blood pressure, blood sugar, and other cardiometabolic improvements also moved back toward baseline. (pmc.ncbi.nlm.nih.gov) A second withdrawal trial found the same pattern with tirzepatide. In SURMOUNT-4, people who switched from tirzepatide to placebo regained weight over the next 52 weeks, while those who stayed on treatment kept losing weight. (clinicaltrials.gov) (jamanetwork.com) A 2026 systematic review in *eClinicalMedicine* said weight regain after stopping a glucagon-like peptide 1 receptor agonist was significant and followed a clear trajectory after withdrawal. A 2025 review called the pattern “disease recurrence,” not proof that the drugs failed. (thelancet.com) (pubmed.ncbi.nlm.nih.gov) The muscle question is more complicated than the viral posts suggest. Reviews in 2025 and 2026 say these drugs reduce fat mass most, but they can also reduce lean mass, and the functional effect of that loss is still being studied. (nature.com 1) (nature.com 2) (nejm.org) Some body-composition studies found lean-mass declines during treatment, while others found lean mass was relatively preserved or its share of total body weight improved as fat fell faster. That is why researchers now emphasize protein intake, resistance training, and follow-up after discontinuation rather than a single muscle-loss number for every patient. (academic.oup.com) (nature.com 1) (nature.com 2) Stopping is common in real life. A 2025 JAMA Network Open study of more than 125,000 U.S. adults with overweight or obesity tracked discontinuation and reinitiation of these drugs within two years, and JAMA said real-world discontinuation estimates run about 50% to 75% at 12 months. (jamanetwork.com 1) (jamanetwork.com 2) The bottom line from the trials is narrower than the social posts but still stark: for many patients, appetite suppression ends when treatment ends, and weight maintenance usually needs another long-term plan. (jamanetwork.com) (pmc.ncbi.nlm.nih.gov)